Beam Therapeutics Inc share price logo

Beam Therapeutics Inc Share Price

NASDAQ: BEAM

Mid Cap

$30.31

+0.13

(+0.43%)

as on

Beam Therapeutics Inc Stock Performance

as on April 15, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $30.07
    $31.54
    downward going graph

    0.79%

    Downside

    4.06%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $15.35
    $36.44
    downward going graph

    49.36%

    Downside

    20.22%

    Upside

    downward going graph

Beam Therapeutics Inc share price movements today

Previous Close
$30.18
Open
$31.07
Volume
1.9M
Day's Low - High
$30.07 - $31.54
52 Week Low - High
$15.35 - $36.44

Beam Therapeutics Inc Historical Returns

1 Month Return
+ 19.95 %
3 Month Return
-14.77 %
1 Year Return
+ 77.53 %
3 Year Return
-3.49 %
5 Year Return
0 %

Beam Therapeutics Inc Stock Fundamentals & Key Indicators

Check Beam Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.8B

EPS (TTM)

-4.314

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-361.4M

Revenue (TTM)

139.7M

Profit Margin

-57.24%

Return On Equity TTM

-8.11%

Beam Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Beam Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Beam Therapeutics Inc image
Beam Therapeutics Inc
BUY$2.8BNANA-57.24%
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$42.7B140.76%138.848.45%
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$111.0B102.67%28.532.94%
BeiGene, Ltd. image
BeiGene, Ltd.
NA$35.6BNA124.865.37%
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$79.2B55.14%18.0531.41%

Stock Returns calculator for Beam Therapeutics Inc Stock including INR - Dollar returns

The Beam Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Beam Therapeutics Inc investment value today

Current value as on today

₹1,92,868

Returns

₹92,868

(+92.87%)

Returns from Beam Therapeutics Inc Stock

₹78,294 (+78.29%)

Dollar Impact

₹14,574 (+14.57%)

Analyst Recommendation on Beam Therapeutics Inc Stock

Based on 21 analysts

BUY

61.90%

Buy

38.10%

Hold

0.00%

Sell

Based on 21 analysts, 61.9% of analysts recommend a 'BUY' rating for Beam Therapeutics Inc. Average target price of $51.2

Beam Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Beam Therapeutics Inc.

What analysts predicted

40.8%UPSIDE

Target Price

$51.2

Current Price

$30.31

Analyzed by

21 Analysts

Target

$51.20

Beam Therapeutics Inc target price $51.2, a slight upside of 40.8% compared to current price of $30.31. According to 21 analysts rating.

Beam Therapeutics Inc Stock’s Investor Sentiment and Interest

Investment in Beam Therapeutics Inc Shares on INDmoney has grown by 6.97% over the past 30 days, indicating increased transactional activity.

Time period: to

Change:6.97% versus previous 30 day period

Search interest for Beam Therapeutics Inc Stock has decreased by -37% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-37% versus previous 30 day period

Beam Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
17
316
7
11
14
30
7
8
9
114
Gross Profit
-82
176
-77
11
-79
-71
-91
-93
-100
108
Operating Income
-108
132
-104
-104
-106
-100
-119
-120
-126
-17
EBITDA
-103
138
-98
-99
-101
-94
-113
-114
-107
260
Interest Expense
12
12
-
14
12
-
-
12
10
10
Depreciation
5
5
5
5
5
15
5
5
5
5
Income Before Tax
-96
144
-98
-91
-96
-90
-109
-102
-112
244
Income Tax Expense
-17
1
5
0
-5
-
-
-
-
-
Net Income
-96
142
-98
-91
-96
-90
-109
-102
-112
244
Net Profit Margin
-558.88%
45.16%
-1331.57%
-773.45%
-677.47%
-300.51%
-1462.78%
-1208.26%
-1162.38%
214.09%

Beam Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
0
0
51
60
377
63
139
Gross Profit
-33
-54
-103
-180
-250
377
-304
117
Operating Income
-45
-75
-132
-392
-338
-176
-415
-383
EBITDA
-45
-71
-128
-230
-324
-146
-393
-29
Interest Expense
-
0
1
0
15
46
49
43
Depreciation
0
3
4
7
14
18
31
22
Income Before Tax
-116
-78
-194
-370
-285
-131
-376
-79
Income Tax Expense
-70
0
61
-29
3
1
0
-
Net Income
-115
-78
-194
-370
-289
-132
-376
-79
Net Profit Margin
0.00%
-435144.44%
-810800.00%
-714.91%
-474.54%
-35.09%
-593.13%
-57.24%

Beam Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
142
-98
-91
-96
-90
-109
-102
-112
244
Operating Cash Flow
135
-99
-83
-88
-76
-103
-76
-81
-83
Investing Cash Flow
98
-53
87
24
126
-125
-170
65
108
Financing Cash Flow
33
2
0
1
3
473
1
1
1
Change in Cash
266
-150
4
-62
53
244
-245
-14
27

Beam Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-116
-78
-194
-370
-289
-132
-376
-79
Operating Cash Flow
-20
-72
-95
-66
22
-149
-347
-345
Investing Cash Flow
-13
-66
-100
-294
-461
71
185
-121
Financing Cash Flow
179
41
322
756
111
276
7
478
Change in Cash
146
-97
126
395
-327
199
-154
11

Global Institutional Holdings in Beam Therapeutics Inc

Funds
Holdings
ARCH VENTURE CORP
4.46%
Amova Asset Management Americas, Inc
4.33%
UBS Asset Mgmt Americas Inc
1.64%
Casdin Capital, LLC
1.57%
Geode Capital Management, LLC
2.35%
See all

Insights on Beam Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, BEAM stock has moved up by 23.2%

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, BEAM has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -112.72M → 244.29M (in $), with an average increase of 146.1% per quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 4 quarters, 7.47M → 114.10M (in $), with an average increase of 38.7% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 63.3% return, outperforming this stock by 66.8%

About Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
OrganisationBeam Therapeutics Inc
Headquarters238 Main Street, Cambridge, MA, United States, 02142
IndustryBiotechnology
CEOMr. John M. Evans M.B.A.
E-voting on sharesClick here to vote

Key Management of Beam Therapeutics Inc

Name

Title

Mr. Sravan Kumar Emany

Chief Financial Officer

Dr. Feng Zhang Ph.D.

Co-Founder

Dr. Manmohan Singh Ph.D.

Chief Technology Officer

Dr. J. Keith Joung M.D., Ph.D.

Co-Founder

Ms. Bethany J. Cavanagh

Senior VP of Finance, Treasurer & Principal Accounting Officer

Mr. John M. Evans M.B.A.

CEO & Director

Dr. Giuseppe Ciaramella Ph.D.

President

Dr. Christine P. Bellon J.D., Ph.D.

Senior VP, Chief Legal Officer & Corporate Secretary

Dr. Amy Simon M.D.

Chief Medical Officer

Dr. David R. Liu Ph.D.

Co-Founder

FAQs

What is Beam Therapeutics Inc share price today?

Beam Therapeutics Inc share price today is $30.31 as on at the close of the market. Beam Therapeutics Inc share today touched a day high of $31.54 and a low of $30.07.

What is the 52 week high and 52 week low for Beam Therapeutics Inc share?

Beam Therapeutics Inc share touched a 52 week high of $36.44 on and a 52 week low of $15.35 on . Beam Therapeutics Inc stock price today i.e. is closed at $30.31,which is 16.82% down from its 52 week high and 97.46% up from its 52 week low.

What is Beam Therapeutics Inc's market capitalisation today?

Beam Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in Beam Therapeutics Inc Stock (BEAM) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Beam Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Beam Therapeutics Inc Shares that will get you 0.0495 shares as per Beam Therapeutics Inc share price of $30.31 per share as on April 15, 2026 at 1:29 am IST.

What is the minimum amount required to buy Beam Therapeutics Inc Stock (BEAM) from India?

Indian investors can start investing in Beam Therapeutics Inc (BEAM) shares with as little as ₹93.082 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹930.82 in Beam Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Beam Therapeutics Inc share’s latest price of $30.31 as on April 15, 2026 at 1:29 am IST, you will get 0.3299 shares of Beam Therapeutics Inc. Learn more about fractional shares .